The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Methylxanthine treatment for apnea in preterm infants
Open accessAbstract
BACKGROUND: Recurrent apnea is common in preterm infants, particularly at very early gestational ages. These episodes of loss of effective breathing can lead to hypoxemia and bradycardia which may be severe enough to require resuscitation including use of positive pressure ventilation. Methylxanthines have been used to stimulate breathing and prevent apnea and its consequences. OBJECTIVES: The objective of this review is to determine if methylxanthine treatment in preterm infants with recurrent apnea leads to a clinically important reduction in apnea and use of intermittent positive pressure ventilation (IPPV), without clinically important side effects. SEARCH STRATEGY: Searches were made of the Oxford Database of Perinatal Trials, MEDLINE, EMBASE, previous reviews including cross references, abstracts of conferences and symposia proceedings, expert informants, journal handsearching mainly in the English language. SELECTION CRITERIA: All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included. DATA COLLECTION AND ANALYSIS: Methodological quality was assessed independently by the two authors. Data were extracted independently by the two authors. Treatment effects were expressed as relative risk (RR) and risk difference (RD) and their 95% confidence intervals, using a fixed effect model. For significant results, the inverse of the risk difference (1/RD) was used to calculate the number needed to treat (NNT). MAIN RESULTS: The results of four trials which enrolled a total of 110 preterm infants with apnea indicate that methylxanthine therapy leads to a reduction in apnea and use of IPPV in the first 2 - 7 days. There are insufficient data to evaluate side effects and no data to examine effects within different gestational age groups. There are no trial data which examine long term effects. REVIEWER'S CONCLUSIONS: Methylxanthines are effective in reducing the number of apneic attacks and the use of mechanical ventilation in the two to seven days after starting treatment. In view of its lower toxicity, caffeine would be the preferred drug. Although the safety of methylxanthine therapy has been suggested in cohort studies, there are no trial data on longterm outcome. In order to indicate which infants are likely to benefit from treatment, there is a need for stratification by gestation and/or other risk factors in future studies. In any future studies the longer term effects of treatment on growth and development should be evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Caffeine Therapy for Apnea of Prematurity
Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., & Tin, W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054065 · Cited by 1,208
Long-Term Effects of Caffeine Therapy for Apnea of Prematurity
Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., & Tin, W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073679 · Cited by 948
Effective Care of the Newborn Infant
Speidel, B. (1992) · Archives of Disease in Childhood · doi:10.1136/adc.67.11.1415-a · Cited by 550
Effective care of the newborn infant
Sinclair, J. C., Bracken, M. B., & Silverman, W. A. (1992) · Oxford University Press eBooks · Cited by 328
Apnea, Sudden Infant Death Syndrome, and Home Monitoring
Committee on Fetus and Newborn (2003) · Pediatrics · doi:10.1542/peds.111.4.914 · Cited by 292
Caffeine for Apnea of Prematurity Trial: Benefits May Vary in Subgroups
Davis, P. G., Schmidt, B., Roberts, R. S., Doyle, L. W., Asztalos, E., Haslam, R., Sinha, S., & Tin, W. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.09.069 · Cited by 228
Charles, B. G., Townsend, S. R., Steer, P. A., Flenady, V., Gray, P. H., & Shearman, A. D. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181898b6f · Cited by 142
Self-citationRespiratory Control Disorders in Infants and Children
Beckerman, R. C., Brouillette, R. T., & Hunt, C. E. (1992) · Medical Entomology and Zoology · Cited by 112
Prophylactic methylxanthines for extubation in preterm infants
Henderson-Smart, D. J., & Davis, P. G. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000139 · Cited by 83
Self-citation
Cited by
Caffeine Therapy for Apnea of Prematurity
Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., & Tin, W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054065 · Cited by 1,208
Long-Term Effects of Caffeine Therapy for Apnea of Prematurity
Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., & Tin, W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073679 · Cited by 948
Poets, C. F., Roberts, R. S., Schmidt, B., Whyte, R. K., Asztalos, E. V., Bader, D., Bairam, A., Moddemann, D., Peliowski, A., Rabi, Y., et al. (2015) · JAMA · doi:10.1001/jama.2015.8841 · Cited by 455
Survival Without Disability to Age 5 Years After Neonatal Caffeine Therapy for Apnea of Prematurity
Schmidt, B. (2012) · JAMA · doi:10.1001/jama.2011.2024 · Cited by 403
Periextubation caffeine in preterm neonates: a randomized dose response trial
Steer, P., Flenady, V., Shearman, A., Lee, T., Tudehope, D., & Charles, B. (2003) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2003.00207.x · Cited by 77
Metadata
- Authors
- Henderson-Smart, D. J., & Steer, P. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2001-07-23
- Issue
- 12
- Pages
- CD000140-CD000140
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2165730367
- Cited by
- 254
- References
- 15
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methylxanthine treatment for apnea in preterm infants. https://app.cochat.ai/papers/10.1002/14651858.cd000140
- The paper
- Henderson-Smart, D. J., & Steer, P. A. (2001). Methylxanthine treatment for apnea in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd000140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.